Baxter Pursues Haemophilia B Gene Therapy with Chatham Therapeutics Collaboration
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 6 (Table of Contents)
Published: 15 Jun-2012
DOI: 10.3833/pdr.v2012.i6.1754 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Baxter International has entered into an exclusive global development and commercialisation agreement with Chatham Therapeutics, an affiliate of Asklepios BioPharmaceutical, for potential treatments for haemophilia B using Chatham’s Biological Nano Particles™ gene therapy technology...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS